Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2012-09-06 15:16:51 UTC |
---|
Update Date | 2022-03-07 02:51:49 UTC |
---|
HMDB ID | HMDB0015019 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Quinapril |
---|
Description | Quinapril, also known as accupril, belongs to the class of organic compounds known as dipeptides. These are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond. Quinapril is a very strong basic compound (based on its pKa). Quinapril inhibits angiotensin converting enzyme, an enzyme which catalyses the formation of angiotensin II from its precursor, angiotensin I. Angiotensin II is a powerful vasoconstrictor and increases blood pressure through a variety of mechanisms. In humans, quinapril is involved in quinapril action pathway. Use in pregnancy and breastfeeding is not recommended. Quinapril is a potentially toxic compound. In 2016 it was the 208th most prescribed medication in the United States with more than 2 million prescriptions. It is an ACE inhibitor and works by decreasing renin-angiotensin-aldosterone system activity. Due to reduced angiotensin production, plasma concentrations of aldosterone are also reduced, resulting in increased excretion of sodium in the urine and increased concentrations of potassium in the blood. It is available as a generic medication. In the United States the wholesale cost of this amount is about US$3.50. |
---|
Structure | CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CC2=CC=CC=C2C[C@H]1C(O)=O InChI=1S/C25H30N2O5/c1-3-32-25(31)21(14-13-18-9-5-4-6-10-18)26-17(2)23(28)27-16-20-12-8-7-11-19(20)15-22(27)24(29)30/h4-12,17,21-22,26H,3,13-16H2,1-2H3,(H,29,30)/t17-,21-,22-/m0/s1 |
---|
Synonyms | Value | Source |
---|
(3S)-2-{N-[(2S)-1-ethoxycarbonyl-4-phenylbutan-2-yl]-L-alanyl}-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid | ChEBI | Quinaprilum | ChEBI | (3S)-2-{N-[(2S)-1-ethoxycarbonyl-4-phenylbutan-2-yl]-L-alanyl}-1,2,3,4-tetrahydroisoquinoline-3-carboxylate | Generator | Accupril | HMDB | Quinapril hydrochloride | HMDB | 2-(2-((1-(Ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid | HMDB |
|
---|
Chemical Formula | C25H30N2O5 |
---|
Average Molecular Weight | 438.5161 |
---|
Monoisotopic Molecular Weight | 438.21547208 |
---|
IUPAC Name | (3S)-2-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid |
---|
Traditional Name | quinapril |
---|
CAS Registry Number | 85441-61-8 |
---|
SMILES | CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CC2=CC=CC=C2C[C@H]1C(O)=O |
---|
InChI Identifier | InChI=1S/C25H30N2O5/c1-3-32-25(31)21(14-13-18-9-5-4-6-10-18)26-17(2)23(28)27-16-20-12-8-7-11-19(20)15-22(27)24(29)30/h4-12,17,21-22,26H,3,13-16H2,1-2H3,(H,29,30)/t17-,21-,22-/m0/s1 |
---|
InChI Key | JSDRRTOADPPCHY-HSQYWUDLSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as dipeptides. These are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organic acids and derivatives |
---|
Class | Carboxylic acids and derivatives |
---|
Sub Class | Amino acids, peptides, and analogues |
---|
Direct Parent | Dipeptides |
---|
Alternative Parents | |
---|
Substituents | - Alpha-dipeptide
- Alpha-amino acid ester
- N-acyl-l-alpha-amino acid
- Alpha-amino acid amide
- Alpha-amino acid or derivatives
- Tetrahydroisoquinoline
- Fatty acid ester
- Aralkylamine
- Monocyclic benzene moiety
- Dicarboxylic acid or derivatives
- Fatty acyl
- Benzenoid
- Tertiary carboxylic acid amide
- Amino acid or derivatives
- Carboxamide group
- Carboxylic acid ester
- Amino acid
- Secondary aliphatic amine
- Carboxylic acid
- Secondary amine
- Azacycle
- Organoheterocyclic compound
- Organonitrogen compound
- Hydrocarbon derivative
- Amine
- Organopnictogen compound
- Organic oxygen compound
- Carbonyl group
- Organic oxide
- Organic nitrogen compound
- Organooxygen compound
- Aromatic heteropolycyclic compound
|
---|
Molecular Framework | Aromatic heteropolycyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | 120 - 130 °C | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 0.0085 g/L | Not Available | LogP | 3.2 | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Quinapril,1TMS,isomer #1 | CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CC2=CC=CC=C2C[C@H]1C(=O)O[Si](C)(C)C | 3316.6 | Semi standard non polar | 33892256 | Quinapril,1TMS,isomer #2 | CCOC(=O)[C@H](CCC1=CC=CC=C1)N([C@@H](C)C(=O)N1CC2=CC=CC=C2C[C@H]1C(=O)O)[Si](C)(C)C | 3304.9 | Semi standard non polar | 33892256 | Quinapril,2TMS,isomer #1 | CCOC(=O)[C@H](CCC1=CC=CC=C1)N([C@@H](C)C(=O)N1CC2=CC=CC=C2C[C@H]1C(=O)O[Si](C)(C)C)[Si](C)(C)C | 3286.0 | Semi standard non polar | 33892256 | Quinapril,2TMS,isomer #1 | CCOC(=O)[C@H](CCC1=CC=CC=C1)N([C@@H](C)C(=O)N1CC2=CC=CC=C2C[C@H]1C(=O)O[Si](C)(C)C)[Si](C)(C)C | 3212.8 | Standard non polar | 33892256 | Quinapril,2TMS,isomer #1 | CCOC(=O)[C@H](CCC1=CC=CC=C1)N([C@@H](C)C(=O)N1CC2=CC=CC=C2C[C@H]1C(=O)O[Si](C)(C)C)[Si](C)(C)C | 4115.1 | Standard polar | 33892256 | Quinapril,1TBDMS,isomer #1 | CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CC2=CC=CC=C2C[C@H]1C(=O)O[Si](C)(C)C(C)(C)C | 3553.5 | Semi standard non polar | 33892256 | Quinapril,1TBDMS,isomer #2 | CCOC(=O)[C@H](CCC1=CC=CC=C1)N([C@@H](C)C(=O)N1CC2=CC=CC=C2C[C@H]1C(=O)O)[Si](C)(C)C(C)(C)C | 3554.3 | Semi standard non polar | 33892256 | Quinapril,2TBDMS,isomer #1 | CCOC(=O)[C@H](CCC1=CC=CC=C1)N([C@@H](C)C(=O)N1CC2=CC=CC=C2C[C@H]1C(=O)O[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 3747.9 | Semi standard non polar | 33892256 | Quinapril,2TBDMS,isomer #1 | CCOC(=O)[C@H](CCC1=CC=CC=C1)N([C@@H](C)C(=O)N1CC2=CC=CC=C2C[C@H]1C(=O)O[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 3619.2 | Standard non polar | 33892256 | Quinapril,2TBDMS,isomer #1 | CCOC(=O)[C@H](CCC1=CC=CC=C1)N([C@@H](C)C(=O)N1CC2=CC=CC=C2C[C@H]1C(=O)O[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 4210.5 | Standard polar | 33892256 |
|
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Quinapril GC-MS (1 TMS) - 70eV, Positive | splash10-000i-3121900000-0dcfc70437ccde433e9d | 2017-10-06 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Quinapril GC-MS (Non-derivatized) - 70eV, Positive | splash10-014i-2419000000-dcbece099cf2c40cab65 | 2017-11-06 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Quinapril GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental LC-MS/MS | LC-MS/MS Spectrum - Quinapril LC-ESI-qTof , Positive-QTOF | splash10-001r-0691700000-82303c3856cd6e62fe34 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Quinapril LC-ESI-qTof , Positive-QTOF | splash10-03di-0012900000-04b3b6ea3f77b8f1dc7f | 2017-09-14 | HMDB team, MONA | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Quinapril 10V, Negative-QTOF | splash10-000f-1009500000-739119c71c43d2886da1 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Quinapril 20V, Negative-QTOF | splash10-002g-2529200000-44c2b54cd17a4afaac8c | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Quinapril 40V, Negative-QTOF | splash10-0032-3911000000-3b415cd9c843c9e15a8b | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Quinapril 10V, Negative-QTOF | splash10-000i-0000900000-183d8231af4eb3b23758 | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Quinapril 20V, Negative-QTOF | splash10-0170-1937400000-ce19e2460a1cf7114f0f | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Quinapril 40V, Negative-QTOF | splash10-03di-0920000000-c0d6a91687c7a7259122 | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Quinapril 10V, Positive-QTOF | splash10-000l-0344900000-464fabf7fdbf745a44ea | 2016-08-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Quinapril 20V, Positive-QTOF | splash10-001i-3893000000-a8c3960669fc104c7ad3 | 2016-08-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Quinapril 40V, Positive-QTOF | splash10-01po-2910000000-71a6777a3ae80c108ff8 | 2016-08-01 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Quinapril 10V, Positive-QTOF | splash10-000i-0023900000-6345f9403bef65cdcb1f | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Quinapril 20V, Positive-QTOF | splash10-014u-0229200000-7e50a200d883930f550a | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Quinapril 40V, Positive-QTOF | splash10-07cu-1900000000-54d41ad46f89d62881f1 | 2021-10-11 | Wishart Lab | View Spectrum |
|
---|
General References | - Valles Prats M, Matas Serra M, Bronsoms Artero J, Mate Benito G, Torguet Escuder P, Mauri Nicolas JM: Quinapril ACE-inhibition effects on adrenergic parameters in moderate essential hypertension. Kidney Int Suppl. 1996 Jun;55:S104-6. [PubMed:8743525 ]
- Pitt B, O'Neill B, Feldman R, Ferrari R, Schwartz L, Mudra H, Bass T, Pepine C, Texter M, Haber H, Uprichard A, Cashin-Hemphill L, Lees RS: The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am J Cardiol. 2001 May 1;87(9):1058-63. [PubMed:11348602 ]
- Yamada S, Muraoka I, Kato K, Hiromi Y, Takasu R, Seno H, Kawahara H, Nabeshima T: Elimination kinetics of quinaprilat and perindoprilat in hypertensive patients with renal failure on haemodialysis. Biol Pharm Bull. 2003 Jun;26(6):872-5. [PubMed:12808303 ]
- Tsikouris JP, Suarez JA, Meyerrose GE, Ziska M, Fike D, Smith J: Questioning a class effect: does ACE inhibitor tissue penetration influence the degree of fibrinolytic balance alteration following an acute myocardial infarction? J Clin Pharmacol. 2004 Feb;44(2):150-7. [PubMed:14747423 ]
- Khan BV, Sola S, Lauten WB, Natarajan R, Hooper WC, Menon RG, Lerakis S, Helmy T: Quinapril, an ACE inhibitor, reduces markers of oxidative stress in the metabolic syndrome. Diabetes Care. 2004 Jul;27(7):1712-5. [PubMed:15220251 ]
- Voors AA, van Geel PP, Oosterga M, Buikema H, van Veldhuisen DJ, van Gilst WH: Vascular effects of quinapril completely depend on ACE insertion/deletion polymorphism. J Renin Angiotensin Aldosterone Syst. 2004 Sep;5(3):130-4. [PubMed:15526248 ]
- Kieback AG, Felix SB, Reffelmann T: Quinaprilat: a review of its pharmacokinetics, pharmacodynamics, toxicological data and clinical application. Expert Opin Drug Metab Toxicol. 2009 Oct;5(10):1337-47. doi: 10.1517/17425250903282773. [PubMed:19761414 ]
|
---|